BioIntelliSense received approval from the US Food and Drug Administration (FDA) in October 2024 for its BioButton Multi-Patient wearable and BioDashboard system, which are designed to enhance virtual care programs in hospitals and extend monitoring capabilities into the home. The development represents a significant advancement in remote patient monitoring (RPM), a need that became crucial during the COVID-19 pandemic, says GlobalData, a leading data and analytics company.

According to GlobalData forecasts, the RPM market will reach $760 million by 2030, up from $548.9 million in 2020, registering a compound annual growth rate (CAGR) of 3.3% over the period. The major players in RPM market include Boston Scientific, GE Healthcare and Medtronic.

Kamilla Kan, Senior Data Scientist, Medical Devices team at GlobalData, comments: “As healthcare systems worldwide faced numerous challenges due to COVID-19 pandemic, the need for scalable, continuous monitoring became critical, particularly for managing patient care beyond traditional hospital settings. As such, RPM devices will become an integral part of the healthcare paradigm for patients globally going forward.”

BioIntelliSense’s innovative solution automates the collection of vital signs and provides real-time data, addressing the post-pandemic demand for efficient, remote healthcare solutions that maintain patient safety and improve clinical outcomes. By shifting from episodic to continuous monitoring, the BioButton Multi-Patient wearable and BioDashboard system help clinicians identify critical changes in a patient’s health status early, ensuring timely and effective treatment.

Kan continues: “This comprehensive approach enhances patient safety, improves clinical workflow efficiency, and supports resource optimization by automating vital sign trend monitoring, reducing manual tasks such as spot-checking and documentation.”

In a rapidly evolving wearable market, companies like Apple, Fitbit, and Garmin have also made strides with health-focused devices, integrating features like heart rate, blood oxygen, and ECG monitoring in consumer wearables.

Kan concludes: “However, BioIntelliSense’s approach is distinct in its medical-grade monitoring capabilities tailored specifically for healthcare settings, addressing the gap between general consumer health tracking and clinical monitoring needs.”